Ellie Merle

“Just wanted to ask about the offender citizen's petition on infagratinib. Can you address how you're thinking about that, and do you see any impact on the review timeline or on the label?”

“So, I guess, of those 10% of patients in the U.S. who switched from VoxoGo by the end of July, I guess, what trends or characteristics are you noticing in those patients versus, say, patients that are more likely to stay on VoxoGo?”

“So, in terms of the DM1 program, what would be good data at the data update in the second half, and how are you thinking about it in the context of the broader competitive landscape in DM1?”

“Just curious if you could give us more color on what a steady state level of second line starts look like. I think you said 80% of starts in 2Q were from the front line, so is 20% a steady state for second-line starts, or do you expect that to decline over time?”

“Just in terms of patient growth, it seemed to accelerate versus the first quarter. I guess what are the drivers of this and your expectations for patient growth from here?”